| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 07/14/2004 | EP1345979B1 Novel polyesters, method for producing the same and depot medicaments produced from these polyesters |
| 07/14/2004 | EP1228067B1 5-membered n-heterocyclic compounds with hypoglycemic and hypolipidemic activity |
| 07/14/2004 | EP1224179B1 Sodium-hydrogen exchanger type 1 inhibitor crystals |
| 07/14/2004 | EP1210350B1 Water soluble sdz-rad esters |
| 07/14/2004 | EP1144368B1 Acetylenic alpha-amino acid-based sulfonamide hydroxamic acid tace inhibitors |
| 07/14/2004 | EP1083924B1 Glucagon-like peptide-1 (glp-1) improves beta-cell response to glucose in subjects with impaired glucose tolerance |
| 07/14/2004 | EP0961775B1 Purine l-nucleosides, analogs and uses thereof |
| 07/14/2004 | CN1513056A Production of bioarailable folic acid |
| 07/14/2004 | CN1512985A Aimoquinoline and aminopyridine derivatives and their use as adenosine A3 ligands |
| 07/14/2004 | CN1512889A Pharmaceutial and/or cosmtic compositions for treatment of localised adiposities and cellulite |
| 07/14/2004 | CN1512887A Chromium/biotin treatment of dyslipidemia and diet-induced post prandial hyperglycemia |
| 07/14/2004 | CN1512878A Lipolysis accelerator, cosmetic skin preparation and food or beverage composition each containing the same, and method for reducing body weight and use |
| 07/14/2004 | CN1512876A Biofunctional hydroxyapatite coatings and microspheres for in-situ drug encapsulation |
| 07/14/2004 | CN1512845A Calorically dense liquid oral supplement |
| 07/14/2004 | CN1511833A Process for preparing isoxazolyl alkyl diketone compound |
| 07/14/2004 | CN1511830A Compound used as antiphlogistic |
| 07/14/2004 | CN1511583A Chinese rose extract and its preparing method and use |
| 07/14/2004 | CN1511576A Medicinal composition for preventing and curing diabetes and its preparing method |
| 07/14/2004 | CN1511565A Method for producing sugar reducing extract granular agent |
| 07/14/2004 | CN1511554A Medicinal composition for treating diabetes |
| 07/14/2004 | CN1511548A Chinese medicine composition for treating diabetes, preparing method and use |
| 07/14/2004 | CN1511537A Novel use of daidzein or isoflavones or pueraria flavonid |
| 07/14/2004 | CN1511534A Total sanchinoside and ferulic acid composition for treating cardio-cerebral vascular disease and diabetes and its use |
| 07/14/2004 | CN1511533A Use of bufadienolide in inhibiting vascularization |
| 07/14/2004 | CN1511521A Use of goldenlarch bark acetic acid inhibiting vascularization |
| 07/14/2004 | CN1157415C Alginate having low molecular weight, method for manufacturing it and its use |
| 07/14/2004 | CN1157406C Novel, ATP-sensitive potassium-channel proteins and genes for the same |
| 07/14/2004 | CN1157401C Neotoralactone, its derivatives and their application in reducing fat and lossing weight |
| 07/14/2004 | CN1157392C 8-Azabicyclo (3,2,1) oct-2-ene and octane derivatives as cholinergic ligands at nicotinic ACH receptors |
| 07/14/2004 | CN1157378C Qunoline derivatives |
| 07/14/2004 | CN1157376C Arylpiperidinopropanol and arylpiperaznipropanol derivatives and pharmaceuticals containing the same |
| 07/14/2004 | CN1157368C Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor (PPAR)a |
| 07/14/2004 | CN1157225C Lectin compositions and uses tehreof |
| 07/14/2004 | CN1157224C Novel amide derives. as growth hormone secretagogues |
| 07/14/2004 | CN1157222C Use of mushroon hydrophilic solvent extract in producing medicine for preventing or curing kidney diseases or food |
| 07/14/2004 | CN1157181C Use of conjugated linoleic acid (CLA) for topical treatment of cellulite |
| 07/13/2004 | US6762326 C2-substituted idan-1-ones and their derivatives, processes for their preparation and their use as pharmaceuticals |
| 07/13/2004 | US6762320 Monoamine oxidase b inhibitors; alzheimer's disease, senile dementia |
| 07/13/2004 | US6762283 Caspase-8 interacting proteins |
| 07/13/2004 | US6762196 Use of 2-amino-4-pyridylmethyl-thiazoline derivatives as inhibitors of inducible no-synthase |
| 07/13/2004 | US6762191 Therapeutic compounds |
| 07/13/2004 | US6762186 Use to treat allergy, nasal congestion, inflammatory and central nervous system-related diseases |
| 07/13/2004 | US6762165 Snail venom; muscular disorders, central nervous system disorders, cardiovascular disorders |
| 07/13/2004 | US6761901 Proliposomal compositions that are advantageously used to deliver biologically active compounds to the gastrointestinal tract after oral administration. |
| 07/13/2004 | CA2453282A1 Method of modulating the basal metabolic rate of a dieting mammal by administration of a metabolic modulating agent to the dieting mammal |
| 07/13/2004 | CA2311356C Method for treating alzheimer's disease |
| 07/13/2004 | CA2268684C Process for alkylating hindered sulfonamides |
| 07/08/2004 | WO2004056869A1 Ghrelin receptor inverse agonist for regulation of feeding behaviours |
| 07/08/2004 | WO2004056777A1 Microsomal triglyceride transfer protein inhibitors |
| 07/08/2004 | WO2004056767A1 1-substituted-3-pyrrolidine derivatives as muscarinic receptor antagonists |
| 07/08/2004 | WO2004056763A2 Novel glucagon antagonists |
| 07/08/2004 | WO2004056745A2 Adamantyl acetamides as 11-beta hydroxysteroid dehydrogenase inhibitors |
| 07/08/2004 | WO2004056744A1 Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors |
| 07/08/2004 | WO2004056740A1 Dicarboxylic acid derivatives as ppar-agonists |
| 07/08/2004 | WO2004056396A1 DOSAGE FORMS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS AND HMG-CoA REDUCTASE INHIBITORS WITH IMPROVED PERFORMANCE |
| 07/08/2004 | WO2004056395A1 Compositions of cholesteryl ester transfer protein inhibitors and hmg-coa reductase inhibitors |
| 07/08/2004 | WO2004056376A1 Pharmaceutical formulations containing nitrate |
| 07/08/2004 | WO2004056375A1 Agent for decreasing appetite and for producing a satiation effect, for reducing weight and for lowering the cholesterol level |
| 07/08/2004 | WO2004056355A1 USE OF α-PHENYLTHIOCARBOXYLIC AND α-PHENYLOXYCARBOXYLIC ACIDS WITH SERUM-GLUCOSE-LOWERING AND SERUM-LIPID-LOWERING ACTIVITY |
| 07/08/2004 | WO2004056324A2 Substituted tricyclic gamma-carbolines as serotonin receptor agonists and antagonists |
| 07/08/2004 | WO2004048352A3 2-cyanopyrrolidines and their analogues as dpp-iv inhibitors |
| 07/08/2004 | WO2004039362A3 Hypoestoxides, derivatives and agonists thereof for use in the treatment and prophylaxis of hyperlipidemia |
| 07/08/2004 | WO2004037791B1 Inhibitors of glycogen synthase kinase 3 |
| 07/08/2004 | WO2004037184A3 Methods for the treatment of skin disorders |
| 07/08/2004 | WO2004032949A8 Argyrolobium roseum plant extracts for treating diabetes |
| 07/08/2004 | WO2004019927A3 Perfluorinated fatty acids for the treatment of obesity, diabetes, hyperlipidaemia, cancer and inflammation |
| 07/08/2004 | WO2004011621A3 Multi-step method for the differentiation of insulin positive, glucose |
| 07/08/2004 | WO2004006853A3 Treatment and prophylaxis with 4-1bb-binding agents |
| 07/08/2004 | WO2003105771A3 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)pyrrolidine-3-carboxylates as edg receptor agonists |
| 07/08/2004 | WO2003103663A3 Substituted pyrrolines as kinase inhibitors |
| 07/08/2004 | WO2003070918A3 Rna interference by modified short interfering nucleic acid |
| 07/08/2004 | WO2003070192A3 Compositions and methods for surrogate antibody modulation of an immune response and transport |
| 07/08/2004 | WO2003042358A3 Methods of using 48149, a human aminopeptidase family member |
| 07/08/2004 | WO2003026591A9 Modification of feeding behavior |
| 07/08/2004 | WO2003024965A3 Heterocyclic compounds that are inhibitors of the enzyme dpp-iv |
| 07/08/2004 | WO2003002058A9 Bone anabolic compounds and methods of use |
| 07/08/2004 | WO2002097060A3 Carbohydrate-associated proteins |
| 07/08/2004 | US20040133011 Useful for therapy of noninsulin-dependent diabetes, hyperglycemia, obesity, insulin resistance, dyslipidemia, hyperlipidemia, hypertension, Metabolic Syndrome |
| 07/08/2004 | US20040133008 Amide compounds |
| 07/08/2004 | US20040132989 Enhancing purity of lactose via demineralization and alcohol precipitation; infant dairy product; veterinary medicine |
| 07/08/2004 | US20040132988 Immunoeffector compounds |
| 07/08/2004 | US20040132828 Polymorphic forms of sertraline hydrochloride |
| 07/08/2004 | US20040132824 Novel methods and compositions for alleviating pain |
| 07/08/2004 | US20040132822 Crystalline solid form of (2S,5Z)-2-amino-7-(ethanimidoylamino)-2-methylhept-5-enoic acid |
| 07/08/2004 | US20040132818 dicarboxylic acids and derivatives; hypolipidemic effect based on activating plasma lipoproteins clearance resulting from decrease in plasma apo C-III; insulin sensitizers; treating obesity by increase in calorigenesis |
| 07/08/2004 | US20040132814 Pharmaceutical compositions |
| 07/08/2004 | US20040132809 Cell adhesion inhibitors |
| 07/08/2004 | US20040132806 polymeric coating with a pH-independent dissolution profile that inhibits the release of the pravastatin in the stomach, and permits release in the intestine; side effect reduction |
| 07/08/2004 | US20040132797 treating of or preventing relapse of depression, anxiety disorders, eating disorders, or urinary incontinence |
| 07/08/2004 | US20040132788 thiazole, oxazole, imidazole, isoxazole and isoxazoline derivatives; treating neurodegenerative disorders or pain. |
| 07/08/2004 | US20040132787 e.g., 2-methyl-2-{4-[3-(4-tert-Butyl-phenyl)-[1,2,4]oxadiazol-5-ylmethoxy]-2-methyl-phenoxy}propionic acid or its ethyl ester; dyslipidemia, syndrome X, heart failure, hypercholesteremia, cardiovascular disease, diabetes, anorexia, etc. |
| 07/08/2004 | US20040132781 Pyrazole compounds useful as protein kinase inhibitors |
| 07/08/2004 | US20040132771 solid amorphous adsorbate provides concentration enhancement of the CETP inhibitor resulting in improved bioavailability |
| 07/08/2004 | US20040132745 carbamoyl-substituted aromatics, e.g., N-(butylcarbamoyl-phenyl-methyl)-6-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-nicotinamide; treating hypercholesterolemia, hypertriglyceridemia, pancreatitis, obesity and diabetic conditions |
| 07/08/2004 | US20040132729 Inhibitors of p38 |
| 07/08/2004 | US20040132725 tyrphostin preparations enriched in certain geometric isomers; treating protein tyrosine kinase related disorders. especially with slow release formulations |
| 07/08/2004 | US20040132722 Glycoprotein-mediated MDR |
| 07/08/2004 | US20040132720 Antidepressants |
| 07/08/2004 | US20040132707 Bactericides, especially gramnegative bacteria; side effect reduction |
| 07/08/2004 | US20040132686 C2,5'- disubstituted and N6, c2,5'- trisubstituted adenosine derivatives and their different uses |